Odonate, Inc

Sanifit is a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for progressive vascular calcification disorders. With offices in Spain and the United States, Sanifit focuses on addressing calciphylaxis and peripheral artery disease in patients with End Stage Kidney Disease (ESKD). Their lead compound, SNF472, is a selective and potent inhibitor of hydroxyapatite crystallization, which is the final common pathway leading to vascular calcification. SNF472 has shown promising results in clinical trials, including reducing coronary artery calcium progression and improving wound healing and pain in ESKD patients. Sanifit is dedicated to advancing the treatment options for calcification disorders and has received orphan drug designation from the FDA and EMA for the treatment of calciphylaxis. Their ongoing research and development efforts aim to provide effective therapies for patients suffering from these debilitating conditions, ultimately improving their quality of life and reducing the risk of cardiovascular diseases associated with vascular calcification.Generated from the website

Revelation Biosciences, Inc. is a San Diego-based company focused on developing innovative therapeutics aimed at rebalancing inflammation to optimize health. Their proprietary formulation, Gemini, is designed to modulate the innate immune system's response to various stressors, significantly reducing inflammation-related damage. In addition to their product pipeline, Revelation Biosciences actively engages in financial activities, including public offerings and organizational changes within its board of directors. The company's commitment to advancing healthcare is reflected in its continuous research and development efforts. Generated from the website

Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.